Amneal Pharmaceuticals, Inc. (AMRX)

USD 7.69

(-4.71%)

EBITDA Summary of Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.'s latest annual EBITDA in 2023 was 500.78 Million USD , down -6.42% from previous year.
Amneal Pharmaceuticals, Inc.'s latest quarterly EBITDA in 2024 Q1 was -10.74 Million USD , down -66.96% from previous quarter.
Amneal Pharmaceuticals, Inc. reported an annual EBITDA of 150.42 Million USD in 2022, up 0.9% from previous year.
Amneal Pharmaceuticals, Inc. reported an annual EBITDA of 450 Million USD in 2021, up 26.81% from previous year.
Amneal Pharmaceuticals, Inc. reported a quarterly EBITDA of 142.87 Million USD for 2024 Q2, up 232.45% from previous quarter.
Amneal Pharmaceuticals, Inc. reported a quarterly EBITDA of N/A for 2023 FY, down -6.42% from previous quarter.

Annual EBITDA Chart of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Historical Annual EBITDA of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Year	EBITDA	EBITDA Growth
2023	500.78 Million USD	-6.42%
2022	150.42 Million USD	0.9%
2021	450 Million USD	26.81%
2020	381.04 Million USD	400.0%
2019	155.19 Million USD	-83.21%
2018	-19.67 Million USD	53.37%
2017	271.13 Million USD	-11.5%
2016	306.96 Million USD	21.22%
2015	252.67 Million USD	3.86%
2014	243.28 Million USD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-10.74 Million USD	-66.96%
2024 Q2	142.87 Million USD	232.45%
2023 FY	- USD	-6.42%
2023 Q4	50.79 Million USD	-62.52%
2023 Q1	98.66 Million USD	-27.05%
2023 Q3	135.55 Million USD	1.96%
2023 Q2	132.94 Million USD	34.74%
2022 Q1	82.28 Million USD	-2.02%
2022 FY	- USD	0.9%
2022 Q4	135.25 Million USD	21.69%
2022 Q3	111.15 Million USD	-5.77%
2022 Q2	117.95 Million USD	43.36%
2021 Q3	60.43 Million USD	-54.44%
2021 Q4	83.97 Million USD	38.97%
2021 Q2	132.63 Million USD	25.82%
2021 Q1	105.41 Million USD	309.98%
2021 FY	- USD	26.81%
2020 Q2	72.81 Million USD	-42.48%
2020 Q4	25.71 Million USD	-59.87%
2020 FY	- USD	400.0%
2020 Q3	64.06 Million USD	-12.01%
2020 Q1	126.59 Million USD	240.01%
2019 Q2	38.29 Million USD	507.19%
2019 Q4	37.23 Million USD	175.02%
2019 FY	- USD	-83.21%
2019 Q1	-9.4 Million USD	-114.75%
2019 Q3	-49.62 Million USD	-229.59%
2018 Q2	103.84 Million USD	20.21%
2018 FY	- USD	53.37%
2018 Q4	63.76 Million USD	-45.33%
2018 Q3	116.62 Million USD	12.31%
2018 Q1	86.38 Million USD	-5.16%
2017 FY	- USD	-11.5%
2017 Q1	53.32 Million USD	-47.72%
2017 Q2	44.6 Million USD	-16.35%
2017 Q3	71.42 Million USD	60.11%
2017 Q4	91.09 Million USD	27.54%
2016 Q4	102.01 Million USD	0.0%
2016 FY	- USD	21.22%
2015 FY	- USD	3.86%
2014 FY	- USD	0.0%

Peer EBITDA Comparison of Amneal Pharmaceuticals, Inc.

Name	EBITDA	EBITDA Difference
Bausch Health Companies Inc.	2.88 Billion USD	82.642%
Catalent, Inc.	-284 Million USD	276.332%
Emergent BioSolutions Inc.	-505.29 Million USD	199.106%
Elanco Animal Health Incorporated	-224 Million USD	323.563%
Perrigo Company plc	646.2 Million USD	22.504%
Teva Pharmaceutical Industries Limited	4.33 Billion USD	88.443%
Zoetis Inc.	3.68 Billion USD	86.41%